Nucleus Biologics’ Post

TODAY at Festival of Biologics | Tackling two tracks: Double the science, double the fun! Join Oren Beske in 'MC, Developability & Analytics' and Mario Pereira in 'Bispecifics & Multispecifics' to learn about leveraging transposase platforms for advance cell line development. Then stop by our booth (#1224) to get more details on how ATUM's Leap-In Transposase® platform can shave months off CMC timeline -- from transfection to RCB in ~10 weeks!

Where do we stand with cell line development? Check out DDW's Fall 2024 article featuring Frank Gesellchen, Assay Development Manager at Sphere Fluidics! Frank Gesellchen, discusses the rising demand for biologics and how innovative tools like Cyto-Mine® are addressing industry challenges. "Minimizing batch-to-batch variability in cell density, clone stability, and product yield is critical for achieving consistent, high-quality biologics production. By identifying high-expressing clones early with Cyto-Mine®, we significantly reduce development timelines and improve downstream efficiency." He also highlights the impact of automated high-throughput screening (HTS) and the role of single-cell analysis in increasing the precision and reliability of therapeutic protein production. Read the article here to discover how we're shaping the future of biotech with innovative solutions: https://bit.ly/4ee6Rj9 #DrugDiscovery #Microfluidics #BioTech

Achieve faster LC analyses for large biomolecules in bioprocessing, drug discovery and drug development labs with high throughput BioResolve Premier Columns. These columns enable rapid ID of clones, which provides real-time insights of #mAb critical quality attributes in under 4 minutes for charge variant and subunit analyses. https://bit.ly/4geeJ5Y

In the November 2024 update of The #GenAI Biotech Report, you will learn about BioPharma GenAI partnerships, positive clinical trial results backed by GenAI, plus more ➡️ https://lnkd.in/e7MCzBV8 📣 To get a monthly update of #GenerativeAI applications in #Pharma and #Biotech, subscribe to the The #GenAI Biotech Report: https://lnkd.in/eViEk6x2

Heading to the 20th Annual PEGS Summit in Boston this May? So are we! We’re excited to bring to the forefront our expertise in bioassays, enzymes for protein analysis, and Lumit™ immunoassays. Aimed at addressing the key needs in biologics drug development, our technologies are crafted for scientists shaping the future. #PEGSsummit #bioassays Dive deeper into how we’re supporting innovation: https://bit.ly/3UturkA

Register Now: https://buff.ly/4ayEmKy “New Modality - Peptide Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform” - Wednesday, Jun 19, 10:00am ET / 7:00am PT / 4:00pm CET - Fierce Biotech and BioDuro-Sundia partner production on peptides drug discovery and peptide synthesis in practice. #PeptidesDiscovery #PeptideDiscovery #PeptideDrugDiscovery #IntegratedDrugDiscovery #BioDuroSundia #Webinar

ME Therapeutics is expanding! We're moving into new lab space to support our drug research and development efforts. This move will allow us to explore new drug discovery opportunities and enhance our pipeline. https://lnkd.in/effQ7kG4 #BioTech #HealthcareInnovation #DrugDiscovery #ResearchAndDevelopment #CorporateGrowth #CancerResearch #NewFacilities #Innovation #ScientificResearch

🌍 Together, we can shape the future of biotechnology. ✨ At Ningaloo Biosystems, we are proud to be at the forefront of biopharmaceutical innovation! 🚀 By controlling cells in real-time, we enable the production of therapeutic proteins that are difficult to make. This not only paves the way to more efficient production but can also significantly improve manufacturing economics. How? Learn more at the upcoming 4th Optogenetic Technologies and Applications Conference in Boston, MA, starting on September 10, 2024. #biopharma #NextGenMedicines #optogenetics

Unravel the secret of XDCs with Leo Liu, Ph.D., as he presents an enlightening webinar on the increasing role of light scattering in XDC development. Get to know how this tech can improve quality control parameters, add vigor to hands-on lab efficiency, and open new realms in the study of complex hybrid biologics. https://lnkd.in/ghVdvupg

🚨 Journal article alert! 🚨 Check out this Review, which compares LC–MS-based approaches for conventional ligand-binding assays and the driving demands in large molecule drug portfolio: https://hubs.ly/Q02xWcnF0